Your browser doesn't support javascript.
loading
Factors Influencing Unfractionated Heparin Pharmacokinetics and Pharmacodynamics During a Cardiopulmonary Bypass.
Gibert, Audrick; Lanoiselée, Julien; Gouin-Thibault, Isabelle; Pontis, Adeline; Azarnoush, Kasra; Petrosyan, Andranik; Grand, Nathalie; Molliex, Serge; Morel, Jérome; Gergelé, Laurent; Hodin, Sophie; Bin, Valérie; Chaux, Robin; Delavenne, Xavier; Ollier, Edouard.
Afiliação
  • Gibert A; INSERM, U1059, Dysfonction Vasculaire et Hémostase, 20 Rue Camelinat, 42000, Saint-Étienne, France. audrick.gibert@gmail.com.
  • Lanoiselée J; INSERM, U1059, Dysfonction Vasculaire et Hémostase, 20 Rue Camelinat, 42000, Saint-Étienne, France.
  • Gouin-Thibault I; Département d'Anesthésie-Réanimation, CHU de Saint-Etienne, Saint-Etienne, France.
  • Pontis A; Laboratory of Hematology, Pontchaillou, University Hospital of Rennes, University of Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR_S 1085, Rennes, France.
  • Azarnoush K; Laboratory of Hematology, Pontchaillou, University Hospital of Rennes, University of Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR_S 1085, Rennes, France.
  • Petrosyan A; Service de Chirurgie Cardiaque, CHU de Saint-Etienne, Saint-Etienne, France.
  • Grand N; Service de Chirurgie Cardiaque, CHU de Saint-Etienne, Saint-Etienne, France.
  • Molliex S; Département d'Anesthésie-Réanimation, CHU de Saint-Etienne, Saint-Etienne, France.
  • Morel J; Département d'Anesthésie-Réanimation, CHU de Saint-Etienne, Saint-Etienne, France.
  • Gergelé L; Département d'Anesthésie-Réanimation, CHU de Saint-Etienne, Saint-Etienne, France.
  • Hodin S; Département d'Anesthésie-Réanimation, CHU de Saint-Etienne, Saint-Etienne, France.
  • Bin V; INSERM, U1059, Dysfonction Vasculaire et Hémostase, 20 Rue Camelinat, 42000, Saint-Étienne, France.
  • Chaux R; INSERM, U1059, Dysfonction Vasculaire et Hémostase, 20 Rue Camelinat, 42000, Saint-Étienne, France.
  • Delavenne X; INSERM, U1059, Dysfonction Vasculaire et Hémostase, 20 Rue Camelinat, 42000, Saint-Étienne, France.
  • Ollier E; Unité de Recherche Clinique Innovation et Pharmacologie, CHU de Saint-Etienne, Saint-Etienne, France.
Clin Pharmacokinet ; 63(2): 211-225, 2024 02.
Article em En | MEDLINE | ID: mdl-38169065
ABSTRACT

BACKGROUND:

Unfractionated heparin (UFH) is commonly used during cardiac surgery with a cardiopulmonary bypass to prevent blood clotting. However, empirical administration of UFH leads to variable responses. Pharmacokinetic and pharmacodynamic modeling can be used to optimize UFH dosing and perform real-time individualization. In previous studies, many factors that could influence UFH pharmacokinetics/pharmacodynamics had not been taken into account such as hemodilution or the type of UFH. Few covariates were identified probably owing to a lack of statistical power. This study aims to address these limitations through a meta-analysis of individual data from two studies.

METHODS:

An individual patient data meta-analysis was conducted using data from two single-center prospective observational studies, where different UFH types were used for anticoagulation. A pharmacodynamic/pharmacodynamic model of UFH was developed using a non-linear mixed-effects approach. Time-varying covariates such as hemodilution and fluid infusions during a cardiopulmonary bypass were considered.

RESULTS:

Activities of UFH's anti-activated factor/anti-thrombin were best described by a two-compartment model. Unfractionated heparin clearance was influenced by body weight and the specific UFH type. Volume of distribution was influenced by body weight and pre-operative fibrinogen levels. Pharmacodynamic data followed a log-linear model, accounting for the effect of hemodilution and the pre-operative fibrinogen level. Equations were derived from the model to personalize UFH dosing based on the targeted activated clotting time level and patient covariates.

CONCLUSIONS:

The population model effectively characterized UFH's pharmacokinetics/pharmacodynamics in cardiopulmonary bypass patients. This meta-analysis incorporated new covariates related to UFH's pharmacokinetics/pharmacodynamics, enabling personalized dosing regimens. The proposed model holds potential for individualization using a Bayesian estimation.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Heparina / Ponte Cardiopulmonar Tipo de estudo: Observational_studies / Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Heparina / Ponte Cardiopulmonar Tipo de estudo: Observational_studies / Prognostic_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article